You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
BioRad aims to return to market growth over the next few years, reach a mid-teens operating margin, and drive further free cash flow expansion, while considering M&A to accelerate portfolio shifts.
BioRad is targeting market growth, a mid-teens operating margin within the next few years, and free cash flow expansion, while third-quarter operating margin reached 12.8%. Fourth-quarter conditions were expected to resemble the third quarter, with headwinds carrying into 27.
Bio-Rad reported third-quarter revenue of approximately $656 million, up 0.5%, as DDPCR instrument revenue grew more than 20% year-over-year and non-GAAP gross margin expanded to 54.5%.
Bio-Rad reported third-quarter 2026 net sales of $656.4 million, up 0.5%, alongside a $588.2 million gain from changes in equity securities and loan receivable fair value. Restructuring charges were $77.6 million.
Bio-Rad Laboratories, Inc. reported third-quarter 2026 net sales of $656.4 million, up 0.5% from $653.0 million. GAAP net income was $458.6 million, substantially reflecting the fair-market-value change in its Sartorius AG investment.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Q3 returned to currency-neutral revenue growth, with Clinical Diagnostics and Droplet Digital PCR leading gains, while non-GAAP margins expanded and management expects a 5% to 6% sequential Q4 revenue ramp. Life Science revenue and free cash flow declined, full-year revenue guidance remains pressured, and restructuring charges plus an intangible-asset impairment drove a GAAP operating loss while Q4 gross margin is expected to decline sequentially.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Clinical Diagnostics currency-neutral sales change | 0.3% | second quarter of 2026 | — |
| Currency-neutral revenue growth (decline) non-GAAP | -3% | six months ended June 30, 2026 | — |
| Currency-neutral sales change | 1.9% | second quarter of 2026 | — |
| Droplet Digital PCR franchise growth | 6% | Q2 2026 | — |
| Free cash flow non-GAAP | $144.8M | six months ended June 30, 2026 | — |
| Gross Margin non-GAAP | 53.9% | Q2 2026 | — |
| Gross margin (non-GAAP) non-GAAP | 53.9% | Q2 2026 | — |
| Life Science currency-neutral revenue change | -5.1% | Q2 2026 | — |
| Life Science currency-neutral sales change | 5.1% | second quarter of 2026 | — |
| Life Science segment currency-neutral revenue growth (decline) non-GAAP | -5.1% | three months ended June 30, 2026 | — |
| Non-GAAP diluted income per share non-GAAP | $2.62 | three months ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP GAAP diluted income (loss) per share $13.85
+$0.22 Amortization of purchased intangibles
+$0.02 Acquisition related (benefits) costs
+$0.03 Restructuring (benefits) costs
+$0.04 European Union's IVDR
-$17.08 (Gains) losses from change in fair market value of equity securities and loan receivable
-$0.25 (Gains) losses on equity-method investments
+$5.79 Income tax effect of non-GAAP adjustments
+$0 Add back anti-dilutive shares
= Non-GAAP diluted income per share $2.62
|
|||
| Non-GAAP effective tax rate non-GAAP | 18.3% | second quarter of 2026 | — |
| Non-GAAP income from operations non-GAAP | $120.4M | six months ended June 30, 2026 | — |
| Non-GAAP net income non-GAAP | $121.1M | six months ended June 30, 2026 | — |
| Operating Margin non-GAAP | 12.5% | Q2 2026 | — |
| Share repurchases | $32M | during the quarter | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BIO
this stock
Bio-Rad Laboratories, Inc.
|
$9.85B | +20.9% | +0.7% | 9.7 | 4.3% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
BioRad is targeting market growth, a mid-teens operating margin within the next few years, and free cash flow expansion, while third-quarter operating margin reached 12.8%. Fourth-quarter conditions were expected to resemble the third quarter, with headwinds carrying into 27.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BIO | -4.0% | +3.6% | +23.4% | -1.6% | +20.9% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -6.6% | +4.7% | +22.9% | -1.4% | +10.3% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
